DIHUA YU to Receptor, ErbB-2
This is a "connection" page, showing publications DIHUA YU has written about Receptor, ErbB-2.
Connection Strength
1.793
-
SRC family kinases as novel therapeutic targets to treat breast cancer brain metastases. Cancer Res. 2013 Sep 15; 73(18):5764-74.
Score: 0.218
-
Upregulation and activation of PKC alpha by ErbB2 through Src promotes breast cancer cell invasion that can be blocked by combined treatment with PKC alpha and Src inhibitors. Oncogene. 2006 Jun 01; 25(23):3286-95.
Score: 0.129
-
Overexpression of ErbB2 in cancer and ErbB2-targeting strategies. Oncogene. 2000 Dec 11; 19(53):6115-21.
Score: 0.091
-
Overexpression of ErbB2 blocks Taxol-induced apoptosis by upregulation of p21Cip1, which inhibits p34Cdc2 kinase. Mol Cell. 1998 Nov; 2(5):581-91.
Score: 0.078
-
The erbB2 gene as a cancer therapeutic target and the tumor- and metastasis-suppressing function of E1A. Cancer Metastasis Rev. 1998 Jun; 17(2):195-202.
Score: 0.076
-
Overexpression of both p185c-erbB2 and p170mdr-1 renders breast cancer cells highly resistant to taxol. Oncogene. 1998 Apr 23; 16(16):2087-94.
Score: 0.076
-
Cross-reactivity of C219 anti-p170(mdr-1) antibody with p185(c-erbB2) in breast cancer cells: cautions on evaluating p170(mdr-1) J Natl Cancer Inst. 1997 Oct 15; 89(20):1524-9.
Score: 0.073
-
Targeting Aberrant p70S6K Activation for Estrogen Receptor-Negative Breast Cancer Prevention. Cancer Prev Res (Phila). 2017 Nov; 10(11):641-650.
Score: 0.072
-
Trastuzumab Increases HER2 Uptake and Cross-Presentation by Dendritic Cells. Cancer Res. 2017 10 01; 77(19):5374-5383.
Score: 0.072
-
Overexpression of the c-erbB-2 gene enhanced intrinsic metastasis potential in human breast cancer cells without increasing their transformation abilities. Cancer Res. 1997 Mar 15; 57(6):1199-205.
Score: 0.070
-
Overexpression of c-erbB-2/neu in breast cancer cells confers increased resistance to Taxol via mdr-1-independent mechanisms. Oncogene. 1996 Sep 19; 13(6):1359-65.
Score: 0.068
-
Liposome-mediated in vivo E1A gene transfer suppressed dissemination of ovarian cancer cells that overexpress HER-2/neu. Oncogene. 1995 Oct 05; 11(7):1383-8.
Score: 0.063
-
PI3K-independent mTOR activation promotes lapatinib resistance and IAP expression that can be effectively reversed by mTOR and Hsp90 inhibition. Cancer Biol Ther. 2015; 16(3):402-11.
Score: 0.060
-
Biomarker-guided sequential targeted therapies to overcome therapy resistance in rapidly evolving highly aggressive mammary tumors. Cell Res. 2014 May; 24(5):542-59.
Score: 0.057
-
Enhanced PI3K p110a signaling confers acquired lapatinib resistance that can be effectively reversed by a p110a-selective PI3K inhibitor. Mol Cancer Ther. 2014 Jan; 13(1):60-70.
Score: 0.056
-
Concomitant targeting of tumor cells and induction of T-cell response synergizes to effectively inhibit trastuzumab-resistant breast cancer. Cancer Res. 2012 Sep 01; 72(17):4417-28.
Score: 0.051
-
Phase I/II study of trastuzumab in combination with everolimus (RAD001) in patients with HER2-overexpressing metastatic breast cancer who progressed on trastuzumab-based therapy. J Clin Oncol. 2011 Aug 10; 29(23):3126-32.
Score: 0.047
-
Combating trastuzumab resistance by targeting SRC, a common node downstream of multiple resistance pathways. Nat Med. 2011 Apr; 17(4):461-9.
Score: 0.046
-
PTEN, PIK3CA, p-AKT, and p-p70S6K status: association with trastuzumab response and survival in patients with HER2-positive metastatic breast cancer. Am J Pathol. 2010 Oct; 177(4):1647-56.
Score: 0.045
-
Upregulation of lactate dehydrogenase A by ErbB2 through heat shock factor 1 promotes breast cancer cell glycolysis and growth. Oncogene. 2009 Oct 22; 28(42):3689-701.
Score: 0.041
-
Mechanisms of disease: understanding resistance to HER2-targeted therapy in human breast cancer. Nat Clin Pract Oncol. 2006 May; 3(5):269-80.
Score: 0.033
-
Mechanisms of ErbB2-mediated paclitaxel resistance and trastuzumab-mediated paclitaxel sensitization in ErbB2-overexpressing breast cancers. Semin Oncol. 2001 Oct; 28(5 Suppl 16):12-7.
Score: 0.024
-
C-erbB-2/ HER-2 upregulates fascin, an actin-bundling protein associated with cell motility, in human breast cancer cell lines. Oncogene. 2000 Oct 05; 19(42):4864-75.
Score: 0.022
-
E1A-mediated paclitaxel sensitization in HER-2/neu-overexpressing ovarian cancer SKOV3.ip1 through apoptosis involving the caspase-3 pathway. Clin Cancer Res. 2000 Jan; 6(1):250-9.
Score: 0.021
-
Heregulin beta1-activated phosphatidylinositol 3-kinase enhances aggregation of MCF-7 breast cancer cells independent of extracellular signal-regulated kinase. Cancer Res. 1999 Apr 01; 59(7):1620-5.
Score: 0.020
-
Mapping of adenovirus 5 E1A domains responsible for suppression of neu-mediated transformation via transcriptional repression of neu. Oncogene. 1997 Apr 24; 14(16):1965-71.
Score: 0.018
-
New strategies in locally advanced breast cancer. Cancer Treat Res. 1997; 90:253-71.
Score: 0.017
-
HER-2/neu-targeting cancer therapy via adenovirus-mediated E1A delivery in an animal model. Oncogene. 1995 May 18; 10(10):1947-54.
Score: 0.015
-
Enhanced chemoresistance by elevation of p185neu levels in HER-2/neu-transfected human lung cancer cells. J Natl Cancer Inst. 1995 May 03; 87(9):682-4.
Score: 0.015
-
c-erbB-2/neu overexpression enhances metastatic potential of human lung cancer cells by induction of metastasis-associated properties. Cancer Res. 1994 Jun 15; 54(12):3260-6.
Score: 0.014
-
Reexpression of neu-encoded oncoprotein counteracts the tumor-suppressing but not the metastasis-suppressing function of E1A. Cancer Res. 1993 Dec 01; 53(23):5784-90.
Score: 0.014
-
Enhanced c-erbB-2/neu expression in human ovarian cancer cells correlates with more severe malignancy that can be suppressed by E1A. Cancer Res. 1993 Feb 15; 53(4):891-8.
Score: 0.013
-
Mechanisms of c-erbB2/neu oncogene-induced metastasis and repression of metastatic properties by adenovirus 5 E1A gene products. Oncogene. 1992 Nov; 7(11):2263-70.
Score: 0.013
-
The retinoblastoma gene product suppresses neu oncogene-induced transformation via transcriptional repression of neu. J Biol Chem. 1992 May 25; 267(15):10203-6.
Score: 0.013
-
The Skp2-SCF E3 ligase regulates Akt ubiquitination, glycolysis, herceptin sensitivity, and tumorigenesis. Cell. 2012 May 25; 149(5):1098-111.
Score: 0.013
-
Expression of activated rat neu oncogene is sufficient to induce experimental metastasis in 3T3 cells. Oncogene. 1991 Nov; 6(11):1991-6.
Score: 0.012
-
Adenovirus type 5 E1A gene products act as transformation suppressors of the neu oncogene. Mol Cell Biol. 1991 Mar; 11(3):1745-50.
Score: 0.012
-
Transcriptional repression of the neu protooncogene by the adenovirus 5 E1A gene products. Proc Natl Acad Sci U S A. 1990 Jun; 87(12):4499-503.
Score: 0.011
-
Overexpression of the c-erbB-2/neu-encoded p185 protein in primary lung cancer. Mol Carcinog. 1992; 5(3):213-8.
Score: 0.003